Publications

Our publications through time

This is a comprehensive list of our laboratory’s publications dating all the way back to 2006, with key publications highlighted

• 2024

  Highlights/Key publications:

  Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukaemia. Cell Rep Med. 2024 Jun 18;5(6):101572. doi: 10.1016/j.xcrm.2024.101572. Epub 2024 May 15. PMID: 38754420; PMCID: PMC11228397. https://pubmed.ncbi.nlm.nih.gov/38754420/

  Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16. J Immunother Cancer. 2024 Apr 11;12(4):e008179. doi: 10.1136/jitc-2023-008179. PMID: 38604812; PMCID: PMC11015285. https://pubmed.ncbi.nlm.nih.gov/38604812/

• 2023

  Highlights/Key publications:

  Gelebart P, Eriksen Gjerstad M, Benjaminsen S, Han J, Karlsen I, Safont MM, Leitch C, Fandalyuk Z, Popa M, Helgeland L, Papp B, Baran-Marszak F, McCormack E. Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells. Blood. 2023 Oct 26;142(17):1478-1493. doi: 10.1182/blood.2022015581. PMID: 37339584. https://pubmed.ncbi.nlm.nih.gov/37339584/

  Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Fernández AP, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D’Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2023 Aug 18;14(1):5019. doi: 10.1038/s41467-023-40764-2. Erratum for: Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. PMID: 37596290; PMCID: PMC10439212. https://pubmed.ncbi.nlm.nih.gov/37596290/

  Others:

  Fosse V, Oldoni E, Bietrix F, Budillon A, Daskalopoulos EP, Fratelli M, Gerlach B, Groenen PMA, Hölter SM, Menon JML, Mobasheri A, Osborne N, Ritskes-Hoitinga M, Ryll B, Schmitt E, Ussi A, Andreu AL, McCormack E; PERMIT group. Recommendations for robust and reproducible preclinical research in personalised medicine. BMC Med. 2023 Jan 8;21(1):14. doi: 10.1186/s12916-022-02719-0. PMID: 36617553; PMCID: PMC9826728. https://pubmed.ncbi.nlm.nih.gov/36617553/

  Steinskog ESS, Finne K, Enger M, Helgeland L, Iversen PO, McCormack E, Wiig H, Tenstad O. Isolation of lymph shows dysregulation of STAT3 and CREB pathways in the spleen and liver during leukaemia development in a rat model. Microcirculation. 2023 Apr;30(2-3):e12800. doi: 10.1111/micc.12800. Epub 2023 Feb 9. Erratum in: Microcirculation. 2024 Feb;31(2):e12850. doi: 10.1111/micc.12850. PMID: 36702790. https://pubmed.ncbi.nlm.nih.gov/36702790/

  Bartaula-Brevik S, Leitch C, Hernandez-Valladares M, Aasebø E, Berven FS, Selheim F, Brenner AK, Rye KP, Hagen M, Reikvam H, McCormack E, Bruserud Ø, Tvedt THA. Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity. J Clin Med. 2023 Aug 25;12(17):5546. doi: 10.3390/jcm12175546. PMID: 37685612; PMCID: PMC10488188. https://pubmed.ncbi.nlm.nih.gov/37685612/

  Thomsen LCV, Kleinmanns K, Anandan S, Gullaksen SE, Abdelaal T, Iversen GA, Akslen LA, McCormack E, Bjørge L. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study. Cancers (Basel). 2023 Oct 23;15(20):5106. doi: 10.3390/cancers15205106. PMID: 37894472; PMCID: PMC10605295. https://pubmed.ncbi.nlm.nih.gov/37894472/

• 2022

  Fosse V, Oldoni E, Gerardi C, Banzi R, Fratelli M, Bietrix F, Ussi A, Andreu AL, McCormack E, The Permit Group. Evaluating Translational Methods for Personalized Medicine-A Scoping Review. J Pers Med. 2022 Jul 19;12(7):1177. doi: 10.3390/jpm12071177. PMID: 35887673; PMCID: PMC9324577. https://pubmed.ncbi.nlm.nih.gov/35887673/

• 2021

  Highlights/Key publications:

  Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E. Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. Br J Haematol. 2021 Apr;193(2):415-419. doi: 10.1111/bjh.17372. Epub 2021 Mar 9. PMID: 33686650; PMCID: PMC8112349. https://pubmed.ncbi.nlm.nih.gov/33686650/

  Others:

  García de Jalón E, Kleinmanns K, Fosse V, Davidson B, Bjørge L, Haug BE, McCormack E. Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. Mol Imaging Biol. 2023 Feb;25(1):144-155. doi: 10.1007/s11307-021-01685-y. Epub 2021 Dec 10. PMID: 34888759; PMCID: PMC9971101. https://pubmed.ncbi.nlm.nih.gov/34888759/

  Eikrem O, Kotopoulis S, Popa M, Mayoral Safont M, Fossan KO, Leh S, Landolt L, Babickova J, Gudbrandsen OA, Gilja OH, Riedel B, Schjøtt J, McCormack E, Marti HP. Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. Pharmaceutics. 2021 Nov 29;13(12):2038. doi: 10.3390/pharmaceutics13122038. PMID: 34959319; PMCID: PMC8703523. https://pubmed.ncbi.nlm.nih.gov/34959319/

  Zhang J, Terán G, Popa M, Madapura H, Ladds MJGW, Lianoudaki D, Grünler J, Arsenian-Henriksson M, McCormack E, Rottenberg ME, Catrina SB, Laín S, Darekar S. DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance. iScience. 2021 May 1;24(5):102494. doi: 10.1016/j.isci.2021.102494. PMID: 34113829; PMCID: PMC8169992. https://pubmed.ncbi.nlm.nih.gov/34113829/

  Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, Torkzaban M, Wallace K, Eisenbrey JR, Brody JR, McCormack E, Forsberg F. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther. 2021 Mar 4;22(3):204-215. doi: 10.1080/15384047.2021.1881026. Epub 2021 Mar 10. PMID: 33691611; PMCID: PMC8043187. https://pubmed.ncbi.nlm.nih.gov/33691611/

  Ruiz de Garibay G, García de Jalón E, Stigen E, Lund KB, Popa M, Davidson B, Safont MM, Rygh CB, Espedal H, Barrett TM, Haug BE, McCormack E. Repurposing ¹⁸F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. Theranostics. 2021 Apr 7;11(12):6044-6057. doi: 10.7150/thno.55092. PMID: 33897898; PMCID: PMC8058731. https://pubmed.ncbi.nlm.nih.gov/33897898/

  Anandan S, Thomsen LCV, Gullaksen SE, Abdelaal T, Kleinmanns K, Skavland J, Bredholt G, Gjertsen BT, McCormack E, Bjørge L. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers (Basel). 2021 Feb 11;13(4):755. doi: 10.3390/cancers13040755. PMID: 33670410; PMCID: PMC7918057. https://pubmed.ncbi.nlm.nih.gov/33670410/

• 2020

  Highlights/Key publications:

  Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I, Chiron D, Bellanger C, Fleury C, Gélébart P, McCormack E, Ledoux D, Thieblemont C, Marzec J, Gribben JG, Cymbalista F, Varin-Blank N, Gardano L, Baran-Marszak F. Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. Oncogene. 2020 Apr;39(14):2934-2947. doi: 10.1038/s41388-020-1183-x. Epub 2020 Feb 7. PMID: 32034308. https://pubmed.ncbi.nlm.nih.gov/32034308/

  Others:

  Kleinmanns K, Fosse V, Bjørge L, McCormack E. The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. J Pers Med. 2020 Nov 27;10(4):255. doi: 10.3390/jpm10040255. PMID: 33260974; PMCID: PMC7712410. https://pubmed.ncbi.nlm.nih.gov/33260974/

  Bjånes T, Kotopoulis S, Murvold ET, Kamčeva T, Gjertsen BT, Gilja OH, Schjøtt J, Riedel B, McCormack E. Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics. 2020 Feb 7;12(2):141. doi: 10.3390/pharmaceutics12020141. PMID: 32046005; PMCID: PMC7076495. https://pubmed.ncbi.nlm.nih.gov/32046005/

  Aasebø E, Berven FS, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M, Døskeland SO, McCormack E, Batth TS, Olsen JV, Bruserud Ø, Selheim F, Hernandez-Valladares M. Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. Cancers (Basel). 2020 Mar 17;12(3):709. doi: 10.3390/cancers12030709. PMID: 32192169; PMCID: PMC7140113. https://pubmed.ncbi.nlm.nih.gov/32192169/

  Haugse R, Langer A, Murvold ET, Costea DE, Gjertsen BT, Gilja OH, Kotopoulis S, Ruiz de Garibay G, McCormack E. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Pharmaceutics. 2020 Nov 6;12(11):1058. doi: 10.3390/pharmaceutics12111058. PMID: 33171947; PMCID: PMC7694645. https://pubmed.ncbi.nlm.nih.gov/33171947/

  Kleinmanns K, Bischof K, Anandan S, Popa M, Akslen LA, Fosse V, Karlsen IT, Gjertsen BT, Bjørge L, McCormack E. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 2020 Jun;56:102782. doi: 10.1016/j.ebiom.2020.102782. Epub 2020 May 23. PMID: 32454401; PMCID: PMC7248428. https://pubmed.ncbi.nlm.nih.gov/32454401/

  Omsland M, Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Tyrosine kinase inhibitors and interferon-α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020 Mar;34(3):3773-3791. doi: 10.1096/fj.201802061RR. Epub 2020 Jan 16. PMID: 31945226; PMCID: PMC10894852. https://pubmed.ncbi.nlm.nih.gov/31945226/

  Kleinmanns K, Fosse V, Davidson B, de Jalón EG, Tenstad O, Bjørge L, McCormack E. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine. 2020 Jun;56:102783. doi: 10.1016/j.ebiom.2020.102783. Epub 2020 May 23. PMID: 32454402; PMCID: PMC7248677. https://pubmed.ncbi.nlm.nih.gov/32454402/

• 2019

  Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma. Cells. 2019 Feb 21;8(2):189. doi: 10.3390/cells8020189. PMID: 30795553; PMCID: PMC6406403. https://pubmed.ncbi.nlm.nih.gov/30795553/

  Bjånes TK, Jordheim LP, Schjøtt J, Kamceva T, Cros-Perrial E, Langer A, Ruiz de Garibay G, Kotopoulis S, McCormack E, Riedel B. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. Drug Metab Dispos. 2020 Mar;48(3):153-158. doi: 10.1124/dmd.119.089334. Epub 2019 Dec 23. PMID: 31871136; PMCID: PMC11022907. https://pubmed.ncbi.nlm.nih.gov/31871136/

  Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukaemia. J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. doi: 10.1007/s00432-019-02931-1. Epub 2019 May 20. PMID: 31111215; PMCID: PMC6571093. https://pubmed.ncbi.nlm.nih.gov/31111215/

• 2018

  Highlights/Key publications

  Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D’Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5. Erratum in: Nat Commun. 2023 Aug 18;14(1):5019. doi: 10.1038/s41467-023-40764-2. PMID: 29549331; PMCID: PMC5856786. https://pubmed.ncbi.nlm.nih.gov/29549331/

  Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D’Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5. Erratum for: Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. PMID: 29789663; PMCID: PMC5964109. https://pubmed.ncbi.nlm.nih.gov/29789663/

  Others:

  Ladds MJGW, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, Bhatia R, Laín S. Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. PLoS One. 2018 Apr 23;13(4):e0195956. doi: 10.1371/journal.pone.0195956. PMID: 29684045; PMCID: PMC5912769. https://pubmed.ncbi.nlm.nih.gov/29684045/

  Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 2018 Jun 25;18(1):684. doi: 10.1186/s12885-018-4591-3. PMID: 29940909; PMCID: PMC6019524. https://pubmed.ncbi.nlm.nih.gov/29940909/

  Zhang B, Durán PA, Piechaczyk L, Fløisand Y, Safont MMS, Karlsen IT, Fandalyuk Z, Tadele D, Mierlo PV, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM; Bjørn Tore Gjertsen Group; Emmet McCormack Group. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica. 2018 May 10; Online ahead of print. doi: 10.3324/haematol.2018.189399. Epub ahead of print. Retraction in: Haematologica. 2019 May;104(5):e229. doi: 10.3324/haematol.2019.220533. PMID: 29748445. https://pubmed.ncbi.nlm.nih.gov/29748445/

• 2017

  Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15. PMID: 28619982. https://pubmed.ncbi.nlm.nih.gov/28619982/

• 2016

  Highlights/Key publications

  Gelebart P, Popa M, McCormack E. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies. Curr Pharm Biotechnol. 2016;17(1):42-51. doi: 10.2174/1389201016666150817095703. PMID: 26278528. https://pubmed.ncbi.nlm.nih.gov/26278528/

  Others:

  Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget. 2016 Feb 16;7(7):8105-18. doi: 10.18632/oncotarget.6991. PMID: 26812881; PMCID: PMC4884979. https://pubmed.ncbi.nlm.nih.gov/26812881/

  Mamaeva V, Niemi R, Beck M, Özliseli E, Desai D, Landor S, Gronroos T, Kronqvist P, Pettersen IK, McCormack E, Rosenholm JM, Linden M, Sahlgren C. Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors. Mol Ther. 2016 May;24(5):926-36. doi: 10.1038/mt.2016.42. Epub 2016 Feb 26. PMID: 26916284; PMCID: PMC4881775. https://pubmed.ncbi.nlm.nih.gov/26916284/

  Suliman S, Mustafa K, Krueger A, Steinmüller-Nethl D, Finne-Wistrand A, Osdal T, Hamza AO, Sun Y, Parajuli H, Waag T, Nickel J, Johannessen AC, McCormack E, Costea DE. Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes. Biomaterials. 2016 Jul;95:11-21. doi: 10.1016/j.biomaterials.2016.04.002. Epub 2016 Apr 6. PMID: 27108402. https://pubmed.ncbi.nlm.nih.gov/27108402/

  Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sørnes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016 Dec 1;7(12):e2497. doi: 10.1038/cddis.2016.392. PMID: 27906185; PMCID: PMC5260983. https://pubmed.ncbi.nlm.nih.gov/27906185/

  Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016 Dec 10;243:172-181. doi: 10.1016/j.jconrel.2016.10.007. Epub 2016 Oct 12. PMID: 27744037. https://pubmed.ncbi.nlm.nih.gov/27744037/

  Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvåle S, Sontum P, Gjertsen BT, Gilja OH, McCormack E. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. J Control Release. 2017 Jan 10;245:70-80. doi: 10.1016/j.jconrel.2016.11.019. Epub 2016 Nov 18. PMID: 27871988. https://pubmed.ncbi.nlm.nih.gov/27871988/

  Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One. 2016 Jun 28;11(6):e0158208. doi: 10.1371/journal.pone.0158208. PMID: 27352023; PMCID: PMC4924861. https://pubmed.ncbi.nlm.nih.gov/27352023/

  Bojan A, Berindan-Neagoe I, Ciurea S, Dima D, Fuji S, Ghiaur G, Grewal R, Mccormack E, Tanase A, Trifa A, Tomuleasa C. Proceedings from the 1st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016. Rom J Intern Med. 2016 Sep 1;54(3):157-160. doi: 10.1515/rjim-2016-0028. PMID: 27658163. https://pubmed.ncbi.nlm.nih.gov/27658163/

• 2015

  Vorobyeva AG, Stanton M, Godinat A, Lund KB, Karateev GG, Francis KP, Allen E, Gelovani JG, McCormack E, Tangney M, Dubikovskaya EA. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging. PLoS One. 2015 Jun 25;10(6):e0131037. doi: 10.1371/journal.pone.0131037. PMID: 26110789; PMCID: PMC4482324. https://pubmed.ncbi.nlm.nih.gov/26110789/

  Haldorsen IS, Popa M, Fonnes T, Brekke N, Kopperud R, Visser NC, Rygh CB, Pavlin T, Salvesen HB, McCormack E, Krakstad C. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS One. 2015 Aug 7;10(8):e0135220. doi: 10.1371/journal.pone.0135220. PMID: 26252891; PMCID: PMC4529312. https://pubmed.ncbi.nlm.nih.gov/26252891/

• 2014

  Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, Gilja OH, Postema M, Gjertsen BT, McCormack E. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Mol Imaging Biol. 2014 Feb;16(1):53-62. doi: 10.1007/s11307-013-0672-5. PMID: 23877869. https://pubmed.ncbi.nlm.nih.gov/23877869/

  Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One. 2014 Mar 4;9(3):e89527. doi: 10.1371/journal.pone.0089527. PMID: 24594904; PMCID: PMC3942384. https://pubmed.ncbi.nlm.nih.gov/24594904/

  Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud Ø, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E, Bhatia R. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukaemia stem cells. Cell Stem Cell. 2014 Oct 2;15(4):431-446. doi: 10.1016/j.stem.2014.08.001. PMID: 25280219; PMCID: PMC4305398. https://pubmed.ncbi.nlm.nih.gov/25280219/

  Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116. PMID: 24885082; PMCID: PMC4032636. https://pubmed.ncbi.nlm.nih.gov/24885082/

  Hampson P, Wang K, Ersvær E, McCormack E, Schüler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience. 2014 Aug 6;1(8):529-39. doi: 10.18632/oncoscience.71. PMID: 25594060; PMCID: PMC4278328. https://pubmed.ncbi.nlm.nih.gov/25594060/

• 2013

  Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget. 2013 Sep;4(9):1527-46. doi: 10.18632/oncotarget.1291. PMID: 24127551; PMCID: PMC3824525. https://pubmed.ncbi.nlm.nih.gov/24127551/

  Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. PLoS One. 2013;8(2):e56276. doi: 10.1371/journal.pone.0056276. Epub 2013 Feb 11. PMID: 23409163; PMCID: PMC3569410. https://pubmed.ncbi.nlm.nih.gov/23409163/

  Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer. 2013 Aug 1;133(3):544-55. doi: 10.1002/ijc.28056. Epub 2013 Feb 27. PMID: 23354685. https://pubmed.ncbi.nlm.nih.gov/23354685/

  Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res. 2013 Dec 1;73(23):7090-100. doi: 10.1158/0008-5472.CAN-13-1560. Epub 2013 Oct 7. PMID: 24101153. https://pubmed.ncbi.nlm.nih.gov/24101153/

  Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT. In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme. Mol Imaging. 2013 May;12(3):161-72. PMID: 23490442. https://pubmed.ncbi.nlm.nih.gov/23490442/

• 2012

  Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, Iwamoto Y, Wang F, Shen K, Hatfield K, Enger M, Shafiee S, McCormack E, Ebert BL, Weissleder R, Yarmush ML, Parekkadan B. Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19638-43. doi: 10.1073/pnas.1208384109. Epub 2012 Nov 12. PMID: 23150542; PMCID: PMC3511730. https://pubmed.ncbi.nlm.nih.gov/23150542/

  McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens JB, Haug BE, Cooper ME, Gjertsen BT. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013 Feb 15;73(4):1276-86. doi: 10.1158/0008-5472.CAN-12-2649. Epub 2012 Dec 10. PMID: 23233739. https://pubmed.ncbi.nlm.nih.gov/23233739/

  McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukaemia. Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12. PMID: 23243270. https://pubmed.ncbi.nlm.nih.gov/23243270/

  McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22. PMID: 23263452; PMCID: PMC3624013. https://pubmed.ncbi.nlm.nih.gov/23263452/

  Hjelle SM, Sulen A, Øye OK, Jørgensen K, McCormack E, Hollund BE, Gjertsen BT. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. J Proteomics. 2012 Dec 5;76 Spec No.:69-78. doi: 10.1016/j.jprot.2012.07.021. Epub 2012 Jul 26. PMID: 22842154. https://pubmed.ncbi.nlm.nih.gov/22842154/

  Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One. 2012;7(11):e48992. doi: 10.1371/journal.pone.0048992. Epub 2012 Nov 14. PMID: 23155442; PMCID: PMC3498369. https://pubmed.ncbi.nlm.nih.gov/23155442/

• 2011

  Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. Am J Physiol Heart Circ Physiol. 2012 Jan;302(2):H391-401. doi: 10.1152/ajpheart.00842.2011. Epub 2011 Nov 18. PMID: 22101523. https://pubmed.ncbi.nlm.nih.gov/22101523/

• 2010

  McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukaemia. Nutr Cancer. 2010;62(5):574-83. doi: 10.1080/01635580903532416. PMID: 20574918. https://pubmed.ncbi.nlm.nih.gov/20574918/

  Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lønning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track – letter. Cancer Res. 2010 Aug 1;70(15):6393-6. doi: 10.1158/0008-5472.CAN-10-1305. Epub 2010 Jul 14. PMID: 20631079. https://pubmed.ncbi.nlm.nih.gov/20631079/

  Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res. 2011 Jan 15;317(2):234-47. doi: 10.1016/j.yexcr.2010.10.009. Epub 2010 Oct 20. PMID: 20969863. https://pubmed.ncbi.nlm.nih.gov/20969863/

• 2009

  Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28. PMID: 20080645; PMCID: PMC2824310. https://pubmed.ncbi.nlm.nih.gov/20080645/

  Røsland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lønning PE, Bjerkvig R, Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009 Jul 1;69(13):5331-9. doi: 10.1158/0008-5472.CAN-08-4630. Epub 2009 Jun 9. PMID: 19509230. https://pubmed.ncbi.nlm.nih.gov/19509230/

  Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leuk Res. 2010 Jan;34(1):77-84. doi: 10.1016/j.leukres.2009.09.005. Epub 2009 Sep 27. PMID: 19786302. https://pubmed.ncbi.nlm.nih.gov/19786302/

  Hofmann M, McCormack E, Mujić M, Rossberg M, Bernd A, Bereiter-Hahn J, Gjertsen BT, Wiig H, Kippenberger S. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009 Aug;11(8):812-22. doi: 10.1593/neo.09662. PMID: 19649211; PMCID: PMC2713396. https://pubmed.ncbi.nlm.nih.gov/19649211/

• 2008

  Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C, Bruserud Ø, Gevaert K, Vandekerckhove J, Døskeland SO. Abolition of stress-induced protein synthesis sensitizes leukaemia cells to anthracycline-induced death. Blood. 2008 Mar 1;111(5):2866-77. doi: 10.1182/blood-2007-07-103242. Epub 2008 Jan 8. PMID: 18182573. https://pubmed.ncbi.nlm.nih.gov/18182573/

• 2007

  Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukaemia cells and serves as a leukaemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol. 2007 Sep;79(3):210-25. doi: 10.1111/j.1600-0609.2007.00899.x. Epub 2007 Jul 26. PMID: 17655707. https://pubmed.ncbi.nlm.nih.gov/17655707/

  McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens JB, Gjertsen BT. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging. 2007 May-Jun;6(3):193-204. PMID: 17532885. https://pubmed.ncbi.nlm.nih.gov/17532885/

• 2006

  Bruserud Ø, McCormack E, Gjertsen BT. Immunotherapy in chronic lymphocytic leukaemia. Cancer Immunol Immunother. 2006 Feb;55(2):185-7. doi: 10.1007/s00262-005-0031-8. Epub 2005 Jul 7. PMID: 16001162; PMCID: PMC11031023. https://pubmed.ncbi.nlm.nih.gov/16001162/

  Bruserud Ø, Tronstad KJ, McCormack E, Gjertsen BT. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukaemia? Cancer Immunol Immunother. 2006 Feb;55(2):221-8. doi: 10.1007/s00262-005-0032-7. Epub 2005 Jul 21. PMID: 16034559; PMCID: PMC11030065. https://pubmed.ncbi.nlm.nih.gov/16034559/

• 2005

  Bruserud Ø, McCormack E, Gjertsen BT. Immunotherapy in chronic lymphocytic leukaemia. Cancer Immunol Immunother. 2006 Feb;55(2):185-7. doi: 10.1007/s00262-005-0031-8. Epub 2005 Jul 7. PMID: 16001162; PMCID: PMC11031023. https://pubmed.ncbi.nlm.nih.gov/16001162/

  Bruserud Ø, Tronstad KJ, McCormack E, Gjertsen BT. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukaemia? Cancer Immunol Immunother. 2006 Feb;55(2):221-8. doi: 10.1007/s00262-005-0032-7. Epub 2005 Jul 21. PMID: 16034559; PMCID: PMC11030065. https://pubmed.ncbi.nlm.nih.gov/16034559/